C-mpl ligand acts primarily as a lineage-specific hematopoietic growth factor by promoting proliferation of megakaryocyte precursors and their differentiation into megakaryocytes and platelets. In addition to the ability of c-mpl ligand to support megakaryocytic development from CD34
Introduction
A heterogeneous group of cytokines have been shown to stimulate megakaryocyte (Mk) development in vitro and in vivo. While some of these cytokines display Mk colony-stimulating activity, eg interleukin-3 (IL-3), stem cell factor (SCF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), several others (IL-6, IL-11 and leukemia inhibitory factor (LIF)) primarily augment Mk growth when added to cultures containing SCF and IL-3. None of these agents were felt to fulfill the requirements attributed to a principal regulator of Mk and platelet development. A detailed overview is given in Ref. 1 .
Identification of the c-mpl gene on the basis of its homology to viral sequences of the murine myeloproliferative leukemia virus proved to be an important step in the search for a thrombopoietic growth factor. The ability of v-mpl ('viral-mpl') to transform hematopoietic progenitor cells, as well as its homology to the cytokine receptor superfamily had indicated that the cellular homologue of v-mpl was a novel cytokine receptor with an initially unknown ligand. Several observations led to the prediction that the c-mpl protein was critically involved in the regulation of megakaryopoiesis: 2 (1) its expression was restricted to CD34
+ bone marrow cells, megakaryocytes and platelets; 3 (2) c-mpl antisense oligonucleotides selectively inhibited megakaryocyte colony formations without affecting erythroid or granulocyte-macrophage colony growth in vitro; 3 (3) c-mpl receptor 'null mice' showed a dramatic decrease in the number of platelets and megakaryocytes. 4 Four of similar recombinant c-mpl ligands were identified by purification of endogenous thrombopoietin and elucidation of its DNA sequence. 5 Intensive clinical investigations have recently focused on two of these molecules, recombinant human thrombopoietin (rhTPO), a glycosylated protein with an amino acid sequence identical to endogenous thrombopoietin, and recombinant human megakaryocyte growth and development factor (rHuMGDF), which corresponds to the non-glycosylated amino-terminal half of thrombopoietin covalently coupled to polyethylene glycol (PEG-rHuMGDF).
A number of in vitro studies using c-mpl ligand showed, that it stimulated development of megakaryocytes from purified populations of murine progenitors in liquid culture. At a later stage of development, c-mpl ligand increased megakaryocyte size, ploidy and expression of surface differentiation and activation markers, such as the integrins gpIb and gpIIb/IIIa. In vitro these growth factor acted synergistically with earlyacting cytokines in supporting megakaryocyte colony formation. The main message of these investigations is the fact that c-mpl ligand alone or in combination with other cytokines supports the proliferation and differentiation of human megakaryocytic cells. [6] [7] [8] In agreement with the prediction that this ligand-receptor pair plays a key role in the regulation of megakaryopoiesis, thrombocytopenic c-mpl receptor 'null mice' displayed dramatically increased levels of circulating TPO, which dropped to normal values within 2 h following infusion of normal murine platelets. Thus, plasma TPO clearance appears to be regulated substantially by formation of c-mpl receptor-ligand complexes in vivo, with subsequent degradation. 9 Elevated endogenous TPO serum levels found in patients with thrombocytopenia following myelosuppressive therapy or primary bone marrow failure are largely consistent with this model. 8 Interestingly, normal TPO levels are observed in patients with ITP, suggesting that TPO binding to megakaryocytes in addition to platelets regulates endogenous serum levels. The endogenous TPO serum levels of patients with various hematological and non-hematological diseases are summarized in Table 1 . 10 
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Preclinical studies
Effect of c-mpl ligands in normal animals
Ulich et al 11 demonstrated that PEG-rHuMGDF in doses from 1 to 500 g/kg injected daily in normal mice causes an initial increase in bone marrow megakaryocytes after 48 h followed by an initial increase in circulating platelets after 72 h. The increase in circulating platelets is accompanied by predictable, but somewhat complex, dose-and time-dependent changes in the size and heterogeneity of platelets. At the highest dose of 500 g/kg/day, splenic and hepatic extramedullary hematopoiesis was noted, a statistically significant increase in myeloid, erythroid and lymphoid cells in the bone marrow was observed.
PEG-rHuMGDF was administered at doses from 0.05 to 2.5 g/kg/day subcutaneously for 28 days in baboons by Harker et al. 12, 13 There was a log-linear relationship between the dose of PEG-rHuMGDF and the marrow megakaryocyte volume, ploidy and number, as well as for peripheral platelet concentration and platelet mass turnover. Platelet morphology and life span were normal. No effects on the leukocyte, neutrophil and erythrocyte counts were seen.
Arnold et al 14 reported from a single injection of 25 g/kg or 250 g/kg of PEG-rHuMGDF in healthy mice. The investigation of bone marrow megakaryocytes showed markedly increase of frequency, size and ploidy on day 3 after injection, with both doses of PEG-rHuMGDF. In contrast to the sustained increase in the frequency of polyploid cells, the level of polyploidization was downregulated on days 6 to 10, but normalized by day 14. The results demonstrate that a single dose of PEG-rHuMGDF is able to expand the megakaryocytic pool, which with subsequent maturation should lead to an increased rate of platelet production. 14 
C-mpl ligands in animals after chemotherapy and/or irradiation 16
In a rhesus monkey model of sublethal irradiation, PEGrMGDF at a dose of 2.5 g/kg/day accelerated platelet recovery when it was given subsequent to total body irradiation. PEG-rMGDF did significantly improve platelet nadir (43 000/l vs 4000/l), duration of thrombocytopenia (platelet count Ͻ20 000/l, 0 days vs 12 days) or time to recovery to baseline levels (day 17 vs day 24) compared with the control group without cytokine treatment. 16 
C-mpl ligands and platelet function
Whereas PEG-rHuMGDF did not induce platelet aggregation in vitro, platelet aggregatory responsiveness induced by thrombin receptor agonist peptide and collagen was transiently enhanced ex vivo during the initial few days of PEGrHuMGDF administration. However, adenosine diphosphateinduced platelet aggregation was not enhanced ex vivo by PEG-rHuMGDF therapy. By measuring of 111 In-platelet deposition and 125 I-fibrin accumulation on segments of homologous endarterectomized aorta and vascular graft interposed in arteriovenous femoral shunts, a minimal thrombo-occlusive risk of PEG-rHuMGDF treatment was observed.
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Clinical trials
Hematopoietic response of administration of c-mpl ligands to humans with normal bone marrow
To determine the clinical activity and safety of c-mpl ligands, the first study using PEG-rHuMGDF in patients with advanced cancer before any chemotherapy was published by Basser et al. 17 Seventeen patients with a median age of 59 were randomly assigned to receive either PEG-rHuMGDF (0.03 to 1.0 g/kg) or placebo in a 3:1 ratio. The study drug was administered daily by subcutaneous injection for up to 10 days. PEG-rHuMGDF produced a dose-dependent increase in platelets count (up to six-fold). Platelets rose from day 6 of PEG-rHuMGDF administration and continued to rise after stopping the drug. The platelet count peaked between days 12 and 18 and remained above 450 000/l for up to 12 days. Platelets taken from patients during PEG-rHuMGDF administration and at the time of peak platelet count were morphologically and functionally normal. These platelets showed no detectable increase in reactivity nor alteration in activation status. There were no changes of white blood cell count or hematocrit. No substantial alterations in performance status, body temperature, vital signs, or body weight were observed during the study. Liver function tests and biochemical parameters, including lactate dehydrogenase and renal function, were unaffected by PEG-rHuMGDF. Coagulation profiles remained unchanged and no patient experienced bruising or bleeding of any grade. No patient developed antibodies to PEG-rHuMGDF. This study showed at first that PEGrHuMGDF produces a dose-dependent, lineage-determinant effect on megakarypoiesis and platelet production and was well tolerated at the doses up to 1.0 g/kg.
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Twelve chemotherapy-naive patients with sarcoma were treated with a single dose (0.3 to 2.4 g/kg) of rhTPO by Vadhan-Raj et al. 18 It was associated with increases (1.3-to 3.6-fold) in platelet counts (baseline mean: 264 000/l). The increase was seen in all dose levels in all patients. The peak response in platelet count was dose-related, increases from baseline of 61%, 107%, 118%, 212% were seen at the 0.3, 0.6, 1.2, and 2.4 g/kg dose levels, respectively. At the highest dose level tested, the platelet count increased to approximately 1 million per microliter or more in two of three patients treated. In addition to the results from the in vivo animal studies, it seems to be possible to stimulate megakaryocytic development in patients with normal bone marrow function by a single dose of thrombopoietin. 18 
Clinical studies of c-mpl ligands for patients who received chemotherapy
The first recently completed clinical study of PEG-rHuMGDF was a double-blind, randomized, placebo-controlled trial in patients with non-small cell lung cancer. 19 This study examined the effects of PEG-rHuMGDF given prior to any chemotherapy and immediately following one cycle of chemotherapy. PEG-rHuMGDF was associated with an increase in the platelet count when given prior to chemotherapy, with a maximum response occurring 1 week after cessation of PEGrHuMGDF. Administration of PEG-rHuMGDF following chemotherapy with carboplatin and paclitaxel resulted in a median increase in platelets of two-to three-fold at the two highest dose levels (3.0 g/kg/day for 3 or 7 days and 5.0 g/kg/day for 3 days, respectively), with the maximum count observed being 1.9 × 10 6 /l. At the two lowest dose levels (0.03 g/kg/day and 0.1 g/kg/day) the increase in platelet counts was not significantly different from placebo. However, no clear dose-response relation was observed, and as with other growth factors there was a wide variation between different individuals. The effect of PEG-rHuMGDF was lineagespecific, with no apparent effect on neutrophil recovery or the hematocrit. 19 In a multicenter study, adult patients with de novo acute myeloid leukemia (AML) were randomized to receive blinded study drug (PEG-rHuMGDF at 2.5 or 5.0 g/kg/day or placebo) for up to 21 doses following induction chemotherapy with daunorubicin, Ara-C and etoposide. 20 Data on the first course of induction chemotherapy are currently available for the first 36 randomized patients (placebo: n = 10; PEGrHuMGDF: n = 24). Median recovery times to an unsupported platelet count of 20 000/l were 22 days for all PEGrHuMGDF patients vs 27 days for placebo patients. A prolonged elevation of platelet counts was observed for up to 3 weeks after the end of PEG-rHuMGDF administration. The effect of PEG-rHuMGDF appeared to be specific to the platelet lineage as the median time to recovery of absolute neutrophil count (ANC) to Ͼ500/l (26 days) and the red blood cell transfusion requirements were similar in the PEG-rHuMGDF and placebo groups. Platelet counts Ͼ1 × 10 6 /l were noted for one patient in the placebo and 12 patients in the PEGrHuMGDF group. The incidence of thrombotic events was not different between the two groups (2 vs 2), and PEG-rHuMGDF was well tolerated. The overall remission rate after the first induction course was 23/36 (64%). These data indicate that PEG-rHuMGDF is a potent stimulus for an increased and prolonged platelet production even in patients with AML. In an ongoing study involving AML patients, administration of PEGrHuMGDF prior to chemotherapy and for a predetermined duration of 7 days is being investigated. 20 
C-mpl ligands and progenitor mobilization
As expected from preclinical and clinical studies, the activity of PEG-rHuMGDF in the peripheral blood was 'lineage spe-cific'. Rasko et al 21 performed a study to investigate the action of PEG-rHuMGDF on levels of progenitor cells in the bone marrow and the peripheral blood in patients with advanced cancer. After administration of 0.03 to 1.0 g/kg, there was no change in frequency of progenitor cells in bone marrow between baseline and day 8 following PEG-rHuMGDF administration at any dose level. In contrast, there were increased levels of day 7 and day 14 GM-CFC, BFU-E and Meg-CFC in the peripheral blood. The earliest time at which increased levels of progenitor cells were detected in peripheral blood was at day 8, with levels apparently continuing to increase at day 12. 21 To analyze the combination of PEG-rHuMGDF and G-CSF for the potency to mobilize progenitor cells into the peripheral blood, G-CSF at a dose of 5.0 g/kg was combined with PEGrHuMGDF at doses from 0.03 to 5 g/kg or placebo for daily injection in a randomized, blinded phase I study by Basser et al. 22 The combination treatment was started the day after the end of intensive chemotherapy consisting of carboplatin 600 mg/m 2 and cyclophosphamide 1200 mg/m 2 in 41 patients with advanced cancer. PEG-rHuMGDF accelerates platelet recovery after this intermediate dose-intensive cytotoxic treatment (recovery to baseline platelet count: 18 vs 22 days). Because it significantly enhances mobilization of peripheral blood progenitor cells by G-CSF (20-to 60-fold) it might also allow more efficient collection of stem cells for autologous or allogeneic transplantation.
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Conclusions
Thrombocytopenia is a clinically relevant manifestation of a variety of hematologic disorders associated with primary hemopoietic failure states, marrow involvement by malignancies or enhanced destruction of mature platelets. Increasingly intensive cytotoxic treatment regimens employed in patients with leukemias, lymphomas and solid tumors are also associated with a considerable incidence and duration of severe thrombocytopenia.
The current armamentarium to prevent life-threatening hemorrhagic events has been limited to platelet transfusions given prophylactically or in the event of a clinically apparent bleeding tendency. While generally effective, drawbacks of platelet transfusions include a small but real risk of transmitting infectious, particularly viral diseases, precipitation of allergic reactions and the induction of antibodies with subsequent refractoriness to platelet transfusions. As a consequence, the clinical availability of a thrombopoietic growth factor had been eagerly awaited prior to the identification of several closely related c-mpl ligands 3 years ago. These growth factors may also provide a unique insight into the physiology of megakaryocyte development and platelet production.
The ability of c-mpl ligands to stimulate thrombocytopoiesis was demonstrated in numerous in vitro and pre-clinical animal studies and has been confirmed in recent randomized clinical trials. It is now well established that both the full length c-mpl receptor ligand referred to as rhTPO and the truncated pegylated rHuMGDF stimulate platelet production in a dose-dependent manner.
The issue of whether clinically relevant thrombocytopenia can be ameliorated has so far been more difficult to resolve. Because severe thrombocytopenia is not commonly seen with standard chemotherapy regimens, clinical studies examining c-mpl ligands for their ability to ameliorate chemotherapyinduced thrombocytopenia will focus on treatment of acute leukemias and bone marrow transplantation.
Clinical studies of PEG-rHuMGDF in acute myeloid leukemia in particular indicate that proper scheduling and dosing of PEG-rHuMGDF may be far more critical for achieving the desired clinical goals than in the case of the clinically established hematopoietic growth factors G-CSF, GM-CSF or erythropoietin. A rational approach to the clinical use of TPO will have to take into account the long half-life time (approximately 20-40 h), a 5-day latency period for increases in platelet production, and clearance kinetics that are dependent on megakaryocyte and platelet mass, and in the case of AML possibly also on c-mpl receptor expression on leukemic blasts. With the increasing availability of pharmacologic and pharmacokinetic data, clinical trials can be designed to address issues such as dosing (eg initial bolus injections of 30 to 50 g/kg followed by lower maintenance doses of 5 to 10 g/kg), frequency (injections daily, on alternate days or weekly) and timing (eg initiation prior to or postchemotherapy) of c-mpl ligand administration. These issues are likely to be also important in the context of financial considerations, as TPO as a new supportive treatment modality will have to compete against the established standard consisting of readily available platelet transfusions.
The potential utility of c-mpl ligands for treatment of myelodysplastic syndromes or aplastic anemias, diseases in which thrombocytopenia is a leading cause of morbidity and mortality, will have to be evaluated in the future. The apparent ability of TPO to stimulate hematopoietic stem cells and to act synergistically with other hematopoietic growth factors will be of particular interest in aplastic anemia.
Possibly the greatest potential of thrombopoietic growth factors in the near future may be in transfusion medicine, to collect and to store platelets from healthy donors or in autologous settings. Mobilization of peripheral blood stem cells and megakaryocytic progenitor cells, and ex vivo expansion of such immature cell populations are other areas of ongoing intensive research. Clearly, a large amount of clinical experience with the c-mpl ligands must be collected before it is known which field is effectively supported by these agents in clinical practice.
